5-Amino-1MQ: The NNMT Inhibitor Story, Carefully Read
5-amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme overexpressed in adipose tissue in obesity and in some tumour contexts. Rodent data are compelling; human clinical trials are absent.
nicotinamide N-methyltransferase — overexpressed in obese adipose tissue and several tumour types.
NNMT consumes methyl donors (SAM) and produces 1-methylnicotinamide; depletes NAD+ salvage substrate.
obesity rodent models show fat loss, improved insulin sensitivity and metabolic improvement with NNMT inhibition.
no published human clinical trials of 5-amino-1MQ as of writing.
5-amino-1MQ is a small-molecule NNMT inhibitor developed in academic and biotech settings. NNMT consumes nicotinamide (a NAD+ precursor) and methyl donors, making it a plausible target for both metabolic and oncology indications. Rodent obesity studies report meaningful fat loss and metabolic improvement. The translation gap to human clinical trials remains unbridged.
Strong rodent mechanism, zero published human trials. The conversation has run far ahead of the evidence.
What it is
NNMT is an enzyme that methylates nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide. It is overexpressed in adipose tissue in obesity, in several tumour types, and in certain metabolic disease contexts.
5-amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of NNMT. Inhibiting NNMT theoretically preserves nicotinamide (a NAD+ salvage precursor) and methyl donors, with downstream effects on adipocyte metabolism and tumour biology.
It is a small molecule, not a peptide. Included here because the metabolic-enzymology and adipose targets place it adjacent to the peptide weight-regulation conversation.
How NNMT inhibition is hypothesised to act
| Layer | What the research describes |
|---|---|
| NAD+ salvage | Preserves nicotinamide substrate for NAD+ resynthesis; raises NAD+ in adipose. |
| Methyl-donor preservation | Reduces SAM consumption; influences methylation-dependent gene expression. |
| Adipocyte energy expenditure | Animal studies suggest increased adipocyte energy expenditure with NNMT loss. |
| Insulin sensitivity | Improved glucose handling in NNMT-knockout and inhibitor-treated rodent models. |
| Tumour biology | Separate body of work in oncology — NNMT overexpression in tumours. |
The mechanism is biochemically coherent. The cellular and animal evidence is solid. The human translation has not started at trial scale.
Rodent vs human evidence
Rodent obesity
Diet-induced obese mice treated with 5-amino-1MQ show reduced adipose mass, improved insulin sensitivity and increased energy expenditure markers in multiple published studies.
Cell models
Cancer and adipocyte cell lines confirm NNMT-inhibition phenotype.
Human trials
Published human clinical trials of 5-amino-1MQ are absent at time of writing. The compound is used as a research reagent.
The structural pattern is familiar: a metabolic target with strong rodent and cell evidence, no human trials, and a parallel commercial market that has emerged in advance of the trial evidence.
The honest position is curiosity about the mechanism, sober assessment of the evidence gap, and care about the assumption that rodent metabolic effects translate to humans. Several historically promising rodent metabolic targets have not translated.
What we know, what's still open
- NNMT biology: Well-characterised.
- NNMT overexpression in obesity: Documented in human tissue studies.
- Rodent inhibitor efficacy: Solid across multiple groups and models.
- Human efficacy: Unknown — no published RCTs.
- Human safety: Unknown at trial scale.
Frequently asked
Why no human trials yet?
Drug-development timelines and prioritisation. NNMT inhibitor programmes exist in both academic and biotech settings; whether 5-amino-1MQ specifically advances to clinic, or a related compound does, remains open.
How is it different from NAD+ precursors?
Different mechanism: NNMT inhibition preserves the substrate pool; NAD+ precursors add to it. The targets and tissues differ.
Is it safe to use as a research compound?
Acute safety in animals appears favourable; human safety is unstudied. Self-use is not advisable on the current evidence.
Is it on the WADA list?
Not currently a named WADA-listed substance, but the prohibited list has broad categories; status of small-molecule metabolic modulators can change. Check current list.
Where to read further
- • Kraus D et al. NNMT in adipose tissue regulates energy metabolism and obesity. Nature 2014.
- • Neelakantan H et al. Small-molecule inhibition of NNMT in obesity. Biochem Pharmacol.
- • Pissios P. NNMT: more than a vitamin B3 methylase. Trends Endocrinol Metab 2017.